← Back to Screener
Estrella Immunopharma, Inc. Warrant (ESLAW)
Price$0.12
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (4W)-0.73%
VGM Score93.65
All Metrics
Price vs S&P 500 (YTD)127.25%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.01M
52-Week High$0.24
13-Week Price Return53.15%
3-Month Return Std Dev376.04%
Year-to-Date Return138.60%
5-Day Price Return25.32%
Month-to-Date Return-11.56%
Price vs S&P 500 (13W)42.64%
Beta1.24x
52-Week Low$0.03
mGradeA
vgmGradeA
Show chart for
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ESLAWEstrella Immunopharma, Inc. Warrant | — | — | A | $0.12 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing ARTEMIS T-cell therapies targeting CD19 and CD22 for blood cancers, solid tumors, and autoimmune diseases. The company's engineered T-cell approach addresses current treatment limitations in oncology and immunology.